arrow
G

Gabriella Scarlatti

national health laboratory service
H指数:43
被引数:6,855

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early Combination Antiretroviral Therapy Initiation During Primary HIV Infection Restricts HIV Reservoirs and Gut-Driven Inflammation but Fails to Rewire the Systemic Cytokine Landscape

早期在原发HIV感染期间启动联合抗逆转录病毒治疗可限制HIV储库和肠道驱动的炎症,但未能重塑系统性细胞因子景观。

2026-03-160
OA
Monitoring broadly neutralising HIV antibody concentrations using microsampling on dried blood spots in infants

使用微采样干血斑监测婴儿中广谱中和HIV抗体的浓度

2026-01-010
OA
HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial

HIV-1包膜三聚体疫苗诱导性别相关的抗体反应差异:一项1期临床试验

2025-11-210
OAAI
Induction of HIV-1-specific antibody-mediated effector functions by native-like envelope trimers in humans

人源天然样-envelope三聚体诱导HIV-1特异性抗体介导的效应功能

2025-10-011
PRE
Viral and immune profiles during the first wave of SARS-CoV-2 infection in hospitalized patients in Sardinia, Italy
2025-02-240
OAAI
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth

使用稳定类天然HIV-1 Env免疫原的实验医学研究能够驱动长期抗体应答,但缺乏广谱中和能力。

2025-02-010
OAAI
The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID

新型冠状病毒肺炎患者免疫反应的纵向特征揭示了疾病严重程度、患者生存率和长期COVID的新预后特征

2024-07-290
OAAI
Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial
2024-07-201
OAAI
PedMAb1 clinical trial: safety assessment of CAP256V2LS to prevent breastmilk HIV transmission in HIV-1 exposed uninfected neonates
2023-12-172
OA
Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens
2023-07-133
OAAI
Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia
2023-05-235
OAAI
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention
2022-12-066
OAAI
Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates
2022-11-257
OAAI
Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaques
2022-10-012
OAAI
A Case Study to Dissect Immunity to SARS-CoV-2 in a Neonate Nonhuman Primate Model

在新生儿非人类灵长类动物模型中解剖对SARS-CoV-2的免疫力的案例研究

2022-05-043
OAAI
Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers
2022-04-212
OAAI